Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11934535 | 0.86 | PIK3CG (0.56) | MEN1KMT2AMAPTGAAPSMB8 | |
| SCHEMBL11336728 | 0.85 | MEN1 (0.66) | MEN1KMT2ALMNAMAPTCYP1A2 | |
| SCHEMBL30612632 | 0.84 | MEN1 (0.64) | MEN1KMT2ALMNAMAPTCYP1A2 | |
| SCHEMBL4285418 | 0.84 | MEN1 (0.64) | MEN1KMT2ALMNAMAPTCYP1A2 | |
| SCHEMBL11449646 | 0.82 | MEN1 (0.62) | MEN1KMT2ALMNAMAPTCYP1A2 | |
| SCHEMBL30612626 | 0.82 | MEN1 (0.62) | MEN1KMT2ALMNAMAPTCYP1A2 | |
| SCHEMBL9447335 | 0.82 | MEN1 (0.62) | MEN1KMT2ALMNAMAPTCYP1A2 | |
| SCHEMBL21104415 | 0.82 | MEN1 (0.62) | MEN1KMT2ALMNAMAPTCYP1A2 | |
| SCHEMBL22042882 | 0.82 | MEN1 (0.62) | MEN1KMT2ALMNAMAPTCYP1A2 | |
| SCHEMBL14518835 | 0.81 | MEN1 (0.61) | MEN1KMT2ALMNAMAPTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9844540-B2 | Combination therapies for treating cancer | REDHILL BIOPHARMA LTD. (IL) | 2017-12-19 | — | — | US | disclosed |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | REDHILL BIOPHARMA LTD. (IL) | 2017-04-06 | — | — | US | disclosed |
| US-20160113954-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | REDHILL BIOPHARMA LTD. (IL) | 2016-04-28 | — | — | US | disclosed |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2016-04-14 | — | — | US | disclosed |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-02 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8309577-B2 | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120095004-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120071652-A1 | Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof | CORNERSTONE THERAPEUTICS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-7863291-B2 | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-7772231-B2 | Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2010-08-10 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-7338961-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH | 2008-02-28 | — | — | US | disclosed |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | ABBVIE INC. | 2007-08-30 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | MEN1 3838/4885KMT2A 2891/4885LMNA 2215/4885 |
| US-20160113954-A1 | THERAPY FOR INHIBITION OF SINGLE-STRANDED RNA VIRUS REPLICATION | RNMT, EIF2AK2, POLRMT | MEN1 4547/4885KMT2A 2632/4885LMNA 1570/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | MEN1 3838/4885KMT2A 2891/4885LMNA 2215/4885 |
| US-20120071652-A1 | Novel Piperazines, Pharmaceutical Compositions and Methods of Use Thereof | CHRNA7, CHRNA5, CHRNA2 | MEN1 4856/4885KMT2A 3473/4885LMNA 2589/4885 |
| US-20120095004-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | MEN1 2111/4885KMT2A 3321/4885LMNA 1777/4885 |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | MEN1 2111/4885KMT2A 3321/4885LMNA 1777/4885 |
| US-20160101104-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | MEN1 3838/4885KMT2A 2891/4885LMNA 2215/4885 |
| US-20150094309-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | MEN1 3838/4885KMT2A 2891/4885LMNA 2215/4885 |
| US-20170095460-A1 | COMBINATION THERAPIES FOR TREATING CANCER | KRAS, ACE, TPMT | MEN1 2303/4885KMT2A 425/4885LMNA 4075/4885 |
| US-20080051415-A1 | Novel piperazines, pharmaceutical compositions and methods of use thereof | CHRNA7, CHRNA5, CHRNA2 | MEN1 4856/4885KMT2A 3473/4885LMNA 2589/4885 |
| US-20070203143-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | MEN1 2427/4885KMT2A 2353/4885LMNA 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.